Celecoxib or Naproxen Treatment Does Not Benefit Depressive Symptoms in Persons Age 70 and Older: Findings From a Randomized Controlled Trial
Open accessThe DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
Abstract
Background Several lines of evidence suggest that inflammatory mechanisms may be involved in the severity and progression of depression. One pathway implicated is the production of prostaglandins via the enzyme cyclooxygenase (COX). Although late-life depression in particular has been associated with inflammation, we know of no published studies using COX inhibitors, such as nonsteroidal anti-inflammatory drugs (NSAIDs), in the treatment of depressive syndromes in this population. Objective To evaluate the effect of the NSAIDs celecoxib and naproxen on depressive symptoms in older adults. Methods The Alzheimer's Disease Anti-inflammatory Prevention Trial was a randomized, placebo-controlled, double-masked clinical trial conducted at six U.S. memory clinics. Cognitively normal volunteers age 70 and older with a family history of Alzheimer-like dementia were randomly assigned to receive celecoxib 200 mg twice daily, naproxen sodium 220 mg twice daily, or placebo. The 30-item version of the Geriatric Depression Scale (GDS) was administered to all participants at enrollment and at yearly follow-up visits. Participants with a GDS score greater than 5 at baseline were classified as depressed. Results Of 2,528 participants enrolled, 2,312 returned for at least one follow-up visit. Approximately one-fifth had significant depressive symptoms at baseline. Mean GDS score, and the percentage with significant depressive symptoms, remained similar over time across all three treatment groups. Furthermore, there was no treatment effect on GDS scores over time in the subgroup of participants with significant depressive symptoms at baseline. In longitudinal analysis using generalized estimating equations (GEE) regression, higher baseline GDS scores, a prior psychiatric history, older age, time in the study, and lower cognition interacting with time, but not treatment assignment, were associated with significantly higher GDS scores over time. Conclusion Treatment with celecoxib or naproxen did not improve depressive symptoms over time compared with placebo. While inflammation has been implicated in late-life depression, these results do not support the hypothesis that inhibition of the COX pathway with these NSAIDs at these doses alleviates depressive symptoms in older adults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a large scale randomized controlled trial designed to evaluate NSAID treatment (celecoxib & naproxen) in approximately 2,500 elderly adults with late-life depression found no significant effect in reducing modified Geriatric Depression Scale (GDS) scores compared to placebo (Fields et al., 2012)”
From A Review of the Relationship between Proinflammatory Cytokines and Major Depressive Disorder (2014) · cites this paper as Fields et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and validation of a geriatric depression screening scale: a preliminary report
Yesavage, J. A., Brink, T. L., Rose, T. L., Lum, O., Huang, V., Adey, M., & Leirer, V. O. (1982) · Journal of Psychiatric Research · doi:10.1016/0022-3956(82)90033-4 · Cited by 15,025
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Vane, J. R., Bakhle, Y. S., & Botting, R. M. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.97 · Cited by 2,734
(1987) · PubMed · Cited by 2,657
Depression in Late Life: Review and Commentary
Blazer, D. G. (2003) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/58.3.m249 · Cited by 2,344
Alexopoulos, G. S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66665-2 · Cited by 2,024
Appendix G: Geriatric Depression Scale
(2015) · Deep Brain Stimulation Management · doi:10.1017/cbo9781316026625.021 · Cited by 1,536
Cytokines and major depression
Schiepers, O. J. G., Wichers, M. C., & Maes, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2004.11.003 · Cited by 1,235
Paroxetine for the prevention of depression induced by high-dose interferon alfa.
Musselman, D. L., Lawson, D. H., Gumnick, J. F., Manatunga, A. K., Penna, S., Goodkin, R. S., Greiner, K., Nemeroff, C. B., & Miller, A. H. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103293441303 · Cited by 1,120
The Relationship of Depression and Stressors to Immunological Assays: A Meta-Analytic Review
Zorrilla, E. P., Luborsky, L., McKay, J. R., Rosenthal, R., Houldin, A., Tax, A., McCorkle, R., Seligman, D. A., & Schmidt, K. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0597 · Cited by 995
The macrophage theory of depression
Smith, R. S. (1991) · Medical Hypotheses · doi:10.1016/0306-9877(91)90272-z · Cited by 931
Geriatric Depression Scale 1983
Yesavage, J. A., Brink, T. L., & Rose, T. L. (1999) · Open Scholarship Institutional Repository (Washington University in St. Louis) · Cited by 887
Capuron, L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00407-9 · Cited by 797
Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., & Neels, H. (1997) · Cytokine · doi:10.1006/cyto.1997.0238 · Cited by 728
Endotoxin produces a depressive-like episode in rats
Yirmiya, R. (1996) · Brain Research · doi:10.1016/0006-8993(95)01415-2 · Cited by 604
Penninx, B. W. J. H., Kritchevsky, S. B., Yaffe, K., Newman, A. B., Simonsick, E. M., Rubin, S., Ferrucci, L., Harris, T., & Pahor, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01811-5 · Cited by 530
Maes, M., Scharpé, S., Meltzer, H. Y., Bosmans, E., Suy, E., Calabrese, J., & Cosyns, P. (1993) · Psychiatry Research · doi:10.1016/0165-1781(93)90027-e · Cited by 439
The criterion validity of the Geriatric Depression Scale: a systematic review
Wancata, J., Alexandrowicz, R., Marquart, B., Weiss, M., & Friedrich, F. (2006) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2006.00888.x · Cited by 408
Akhondzadeh, S., Jafari, S., Raisi, F., Nasehi, A. A., Ghoreishi, A., Salehi, B., Mohebbi-Rasa, S., Raznahan, M., & Kamalipour, A. (2009) · Depression and Anxiety · doi:10.1002/da.20589 · Cited by 397
Anti-inflammatory and side effects of cyclooxygenase inhibitors.
Süleyman, H., Demircan, B., & Karagöz, Y. (2007) · PubMed · Cited by 390
Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354
Increased interleukin-6 expression by microglia from brain of aged mice
Ye, S.-M., & Johnson, R. W. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00217-3 · Cited by 327
Inflammatory markers in late-life depression: Results from a population-based study
Bremmer, M. A., Beekman, A. T. F., Deeg, D. J. H., Penninx, B. W. J. H., Dik, M. G., Hack, C. E., & Hoogendijk, W. J. G. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.07.002 · Cited by 326
Godbout, J. P., Moreau, M., Lestage, J., Chen, J., Sparkman, N. L., Connor, J. O., Castanon, N., Kelley, K. W., Dantzer, R., & Johnson, R. W. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301649 · Cited by 299
Nery, F. G., Monkul, E. S., Hatch, J. P., Fonseca, M., Zunta‐Soares, G. B., Frey, B. N., Bowden, C. L., & Soares, J. C. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.912 · Cited by 298
Increase in Interleukin-1β in Late-Life Depression
Thomas, A. J., Davis, S., Morris, C., Jackson, E., Harrison, R., & O’Brien, J. T. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.175 · Cited by 291
Cytokines and Sickness Behavior
DANTZER, R., BLUTHÉ, R., LAYÉ, S., BRET‐DIBAT, J., PARNET, P., & KELLEY, K. W. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb09597.x · Cited by 288
Inhibitors of cyclooxygenases: mechanisms, selectivity and uses.
Botting, R. M. (2006) · PubMed · Cited by 253
Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S., & Brunello, N. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200607000-00005 · Cited by 229
Yirmiya, R. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00226-8 · Cited by 224
van den Biggelaar, A. H. J., Gussekloo, J., de Craen, A. J. M., Frölich, M., Stek, M. L., van der Mast, R. C., & Westendorp, R. G. J. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2007.01.011 · Cited by 209
Inflammatory Proteins and Depression in the Elderly
Tiemeier, H., Hofman, A., van Tuijl, H. R., Kiliaan, A. J., Meijer, J., & Breteler, M. M. B. (2003) · Epidemiology · doi:10.1097/00001648-200301000-00025 · Cited by 206
Depression, immunocompetence, and prostaglandins of the E series
Calabrese, J. R., Skwerer, R. G., Barna, B., Gulledge, A. D., Valenzuela, R., Butkus, A., Subichin, S., & Krupp, N. E. (1986) · Psychiatry Research · doi:10.1016/0165-1781(86)90040-5 · Cited by 205
Ye, S.-M., & Johnson, R. W. (2001) · Neuroimmunomodulation · doi:10.1159/000049025 · Cited by 203
Casolini, P., Catalani, A., Zuena, A. R., & Angelucci, L. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10192 · Cited by 174
Comorbid depression in rheumatoid arthritis: Pathophysiology and clinical implications
Bruce, T. O. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0042-1 · Cited by 163
CSF Prostaglandin Levels in Depressed and Schizophrenic Patients
Linnoila, M. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790040059008 · Cited by 151
Guo, J.-Y., Li, C.-Y., Ruan, Y.-P., Sun, M., Qi, X.-L., Zhao, B.-S., & Luo, F. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.03.076 · Cited by 148
Milaneschi, Y., Corsi, A. M., Penninx, B. W., Bandinelli, S., Guralnik, J. M., & Ferrucci, L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.011 · Cited by 148
Increased level of salivary prostaglandins in patients with major depression
Ohishi, K., Ueno, R., Nishino, S., Sakai, T., & Hayaishi, O. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90283-1 · Cited by 142
Elevated levels of prostaglandin e2 and thromboxane B2 in depression
Lieb, J., Karmali, R. A., & Horrobin, D. F. (1983) · Prostaglandins Leukotrienes and Medicine · doi:10.1016/0262-1746(83)90048-3 · Cited by 141
Debruyne, H., Van Buggenhout, M., Le Bastard, N., Aries, M., Audenaert, K., De Deyn, P. P., & Engelborghs, S. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2154 · Cited by 136
Depression and Immunity: Inflammation and Depressive Symptoms in Multiple Sclerosis
Gold, S. M., & Irwin, M. R. (2009) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2009.02.008 · Cited by 136
Increased plasma levels of 8-iso-PGF2α and IL-6 in an elderly population with depression
Dimopoulos, N., Piperi, C., Psarra, V., Lea, R. W., & Kalofoutis, A. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.07.019 · Cited by 118
REVIEW: Biological risk factors for late life depression
Tiemeier, H. W. (2003) · European Journal of Epidemiology · doi:10.1023/a:1025388203548 · Cited by 111
Myint, A. M., Steinbusch, H. W. M., Goeghegan, L., Luchtman, D., Kim, Y. K., & Leonard, B. E. (2007) · Neuroimmunomodulation · doi:10.1159/000107420 · Cited by 109
Brunello, N., Alboni, S., Capone, G., Benatti, C., Blom, J. M. C., Tascedda, F., Kriwin, P., & Mendlewicz, J. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200607000-00004 · Cited by 104
Schiepers, O. J. G., Wichers, M., & Maes, M. H. J. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.02.001 · Cited by 97
Salivary prostaglandin concentrations: possible state indicators for major depression
(1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.3.365 · Cited by 88
West, D. V., & Maes, M. H. J. (1999) · PubMed · Cited by 84
Depression and Immunity: Inflammation and Depressive Symptoms in Multiple Sclerosis
Gold, S. M., & Irwin, M. R. (2006) · Neurologic Clinics · doi:10.1016/j.ncl.2006.03.007 · Cited by 82
Morrow, S. (1999) · AJN American Journal of Nursing · doi:10.1097/00000446-199901000-00027 · Cited by 71
Yirmiya, R., Barak, O., Avitsur, R., Gallily, R., & Weidenfeld, J. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01295-4 · Cited by 45
Cited by
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Ferrucci, L., & Fabbri, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0064-2 · Cited by 3,690
Köhler, O., Benros, M. E., Nordentoft, M., Farkouh, M. E., Iyengar, R. L., Mors, O., & Krogh, J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1611 · Cited by 941
A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly
Wongrakpanich, S., Wongrakpanich, A., Melhado, K., & Rangaswami, J. (2018) · Aging and disease · doi:10.14336/ad.2017.0306 · Cited by 917
“[41] Fields C, Drye L, Vaidya V, Lyketsos C (2012).”
BackgroundKreisel, T., Frank, M. G., Licht, T., Reshef, R., Ben-Menachem-Zidon, O., Baratta, M. V., Maier, S. F., & Yirmiya, R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.155 · Cited by 663
Inflammation in Depression and the Potential for Anti-Inflammatory Treatment
Kohler, O., Krogh, J., Mors, O., & Eriksen Benros, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666151208113700 · Cited by 516
“On the other hand; 12 month treatment with naproxen among 1,757 healthy users had no impact on depressive symptoms [43].”
BackgroundInfluential
Metadata
- Authors
- Fields, C., Drye, L., Vaidya, V., & Lyketsos, C.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Lyketsos, Constantine
- Venue
- The American Journal of Geriatric Psychiatry
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 20
- Issue
- 6
- Pages
- 505-513
- ISSN
- 1064-7481 (ISSN-L)
- PMC
- PMC3209494
- OpenAlex
- W2095272329
- Cited by
- 96
- References
- 56
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 9 · 2020: 7 · 2019: 7 · 2018: 9 · 2017: 8 · 2016: 9 · 2015: 7 · 2014: 7 · 2013: 5 · 2012: 4
- FWCI
- 1.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- American Journal of Geriatric Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (U01AG015477, P50AG005146, U01-AG15477)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- celecoxib, naproxen, nonsteroidal anti-inflammatory drugs, geriatric depression, depressive symptoms, cyclooxygenase inhibition, inflammation, Alzheimer's disease prevention, Geriatric Depression Scale, cognitive decline
- MeSH terms
- Celecoxib, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Depression, Female, Humans, Longitudinal Studies, Male, Naproxen, Pyrazoles, Sulfonamides, Treatment Outcome, Cyclooxygenase 2 Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.